Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?

Table 3 Cox proportional hazards analysis

Variables	Simple analysis		Multiple analysis
Variables	HR (95% CI)	p-value	cHR (95% CI)	p-value
Surgical resection and if so involved lymph nodes
Surgical resection with NO involved lymph nodes vs No surgical resection	0.30 (0.15 - 0.61)	0.001	0.30 (0.14 - 0.65)	0.002
Surgical resection with involved lymph nodes vs Surgical resection with NO involved lymph nodes	1.65 (0.80 - 3.39)	0.172	1.62 (0.77 - 3.42)	0.206
Surgical resection with involved lymph nodes vs No surgical resection	0.49 (0.30 - 0.81)	0.005	0.49 (0.29 - 0.82)	0.007
Neoadjuvant chemotherapy administered and if so RECIST
NACHT with stable disease or progression vs No NACHT	0.63 (0.31 - 1.26)	0.191	0.66 (0.33 - 1.33)	0.249
NACHT with stable disease or progression vs NACHT with response	0.86 (0.41 - 1.79)	0.682	0.71 (0.34 - 1.49)	0.365
NACHT with response vs No NACHT	0.73 (0.45 - 1.19)	0.213	0.94 (0.55 - 1.59)	0.804
NCCN classification (LA vs BR)	1.13 (0.73 - 1.76)	0.583	1.01 (0.63 - 1.62)	0.976

RECIST Response evaluation criteria in solid tumors, NACHT Neoadjuvant chemotherapy, NCCN National Comprehensive Cancer Network, LA Locally advanced pancreatic ductal adenocarcinoma, BR Borderline resectable pancreatic ductal adenocarcinoma

ISSN: 1471-2482